Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Cyxone's CEO comments on the US patent notice

Cyxone

Biotech company Cyxone develops new therapies for the treatment of autoimmune diseases, such as rheumatoid arthritis with the phase IIb candidate Rabeximod. The company reached a milestone in receiving a Notice of Allowance for the US patent of Rabeximod compounds. BioStock contacted CEO Carl-Magnus Högerkorp for a comment on the prospects of the patent. 

Read the interview with Cyxone's CEO Carl-Magnus Högerkorp at biostock.se:

https://www.biostock.se/en/2023/04/cyxones-ceo-comments-on-the-us-patent-notice/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.